The Ratings Game: Drug maker ChemoCentryx shares rocket on blockbuster potential in rare autoimmune disease

admin 5 years ago No Comments

This post was originally published on this site

A set of conclusive findings from a late-stage clinical trial testing ChemoCentryx Inc.’s experimental vasculitis treatment surprised company executives and investors, who now say they are bullish on the sales and pipeline potential of avacopan.

Prev Article Next Article

Coronavirus Update: New U.S. COVID-19 cases and deaths tick higher, while CDC’s ‘real world’ study shows Pfizer, Moderna vaccines reduce infection risk by 91%

admin June 8, 2021

Deep Dive: These 62 stocks in the S&P 500 soared at least 20% on Tuesday

admin March 24, 2020

Some mental-health professionals find it hard to seek help — and can suffer from even greater stigma

admin October 4, 2019

Need to Know: Don’t get too excited about progress on Trump’s ‘greatest and biggest deal ever’

admin October 14, 2019

Economic Report: OECD boosts economic outlook but warns against tightening policy too quickly

admin September 16, 2020

Market Snapshot: Longest winning stretch in two years on the line as S&P 500 and Nasdaq 100 futures trade at record highs

admin November 9, 2021

About The Author

admin

in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

By signing up above you will receive the Daily Buzz Offers newsletter and 3rd party advertisements. Expect up to 5 messages per week from us. You can unsubscribe at any time at the bottom of any of our emails.

Related Posts

About The Author

admin